Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EBITDA (2016 - 2025)

Historic EBITDA for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$594147.0.

  • China Pharma Holdings' EBITDA rose 3938.96% to -$594147.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 million, marking a year-over-year increase of 2726.52%. This contributed to the annual value of -$4.9 million for FY2024, which is 5215.74% down from last year.
  • Latest data reveals that China Pharma Holdings reported EBITDA of -$594147.0 as of Q3 2025, which was up 3938.96% from -$508104.0 recorded in Q2 2025.
  • China Pharma Holdings' 5-year EBITDA high stood at -$270654.0 for Q1 2023, and its period low was -$1.5 million during Q2 2022.
  • Moreover, its 5-year median value for EBITDA was -$977467.0 (2024), whereas its average is -$952295.3.
  • In the last 5 years, China Pharma Holdings' EBITDA tumbled by 350233.43% in 2021 and then skyrocketed by 7232.13% in 2023.
  • Over the past 5 years, China Pharma Holdings' EBITDA (Quarter) stood at -$836967.0 in 2021, then fell by 29.12% to -$1.1 million in 2022, then dropped by 2.37% to -$1.1 million in 2023, then dropped by 29.03% to -$1.4 million in 2024, then soared by 58.38% to -$594147.0 in 2025.
  • Its EBITDA was -$594147.0 in Q3 2025, compared to -$508104.0 in Q2 2025 and -$778056.0 in Q1 2025.